

# Marco Proietti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7875983/publications.pdf>

Version: 2024-02-01

204  
papers

5,326  
citations

76196

40  
h-index

123241

61  
g-index

213  
all docs

213  
docs citations

213  
times ranked

6177  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherence to the "Atrial Fibrillation Better Care"™ Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes—A Systematic Review and Meta-Analysis of 285,000 Patients. <i>Thrombosis and Haemostasis</i> , 2022, 122, 406-414.	1.8	219
2	Adherence to oral anticoagulant therapy in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2017, 117, 209-218.	1.8	161
3	COVID-19 in Italy: Ageism and Decision Making in a Pandemic. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 576-577.	1.2	139
4	Platelet Activation Is Associated With Myocardial Infarction in Patients With Pneumonia. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1917-1925.	1.2	134
5	Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. <i>American Journal of Medicine</i> , 2018, 131, 1359-1366.e6.	0.6	129
6	Asymptomatic versus symptomatic atrial fibrillation: A systematic review of age/gender differences and cardiovascular outcomes. <i>International Journal of Cardiology</i> , 2015, 191, 172-177.	0.8	125
7	Contemporary stroke prevention strategies in 11%096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. <i>Europace</i> , 2018, 20, 747-757.	0.7	118
8	Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1452-1464.	1.2	107
9	Is There an Obesity Paradox for Outcomes in Atrial Fibrillation?. <i>Stroke</i> , 2017, 48, 857-866.	1.0	102
10	Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation. <i>Stroke</i> , 2018, 49, 98-106.	1.0	102
11	Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. <i>American Journal of Medicine</i> , 2016, 129, 600-607.	0.6	101
12	Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals. <i>PLoS Medicine</i> , 2019, 16, e1002903.	3.9	90
13	Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e014932.	1.6	84
14	Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. <i>Clinical Research in Cardiology</i> , 2016, 105, 412-420.	1.5	78
15	Frailty: What Is It?. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1216, 1-7.	0.8	77
16	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. <i>Europace</i> , 2018, 20, 1399-1421.	0.7	75
17	Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. <i>Europace</i> , 2021, 23, 174-183.	0.7	74
18	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019, 21, 7-8.	0.7	72

#	ARTICLE	IF	CITATIONS
19	Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes. <i>Cardiovascular Research</i> , 2021, 117, 1-21.	1.8	67
20	Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2427-2436.	1.4	66
21	Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. <i>Clinical Research in Cardiology</i> , 2016, 105, 912-920.	1.5	63
22	Influence of gender, age and BMI on lower limb muscular power output in a large population of obese men and women. <i>International Journal of Obesity</i> , 2004, 28, 91-98.	1.6	57
23	Prevalence and Impact of Atrial Fibrillation in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2490.	1.0	56
24	“Real-world” atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. <i>Europace</i> , 2016, 19, euw112.	0.7	55
25	A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme. <i>Europace</i> , 2016, 18, euw069.	0.7	55
26	Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2019, 208, 123-131.	1.2	54
27	Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. <i>Europace</i> , 2020, 22, 33-46.	0.7	54
28	Sex differences in stroke and major adverse clinical events in patients with atrial fibrillation: A systematic review and meta-analysis of 993,600 patients. <i>International Journal of Cardiology</i> , 2018, 269, 182-191.	0.8	53
29	Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 938-946.	0.8	52
30	The energy cost of cycling in young obese women. <i>European Journal of Applied Physiology</i> , 2006, 97, 16-25.	1.2	51
31	Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. <i>European Journal of Internal Medicine</i> , 2018, 55, 28-34.	1.0	51
32	Prevalence of Peripheral Artery Disease by Abnormal Ankle-Brachial Index in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2255-2256.	1.2	49
33	Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. <i>Scientific Reports</i> , 2016, 6, 24376.	1.6	49
34	Prevalence of right ventricular dysfunction and impact on all-cause death in hospitalized patients with COVID-19: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2021, 11, 17774.	1.6	49
35	Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. <i>Canadian Journal of Cardiology</i> , 2019, 35, 619-633.	0.8	48
36	Frailty prevalence and impact on outcomes in patients with atrial fibrillation: A systematic review and meta-analysis of 1,187,000 patients. <i>Ageing Research Reviews</i> , 2022, 79, 101652.	5.0	48

#	ARTICLE	IF	CITATIONS
37	Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAME-TT <sub>2</sub> R <sub>2</sub> score. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 150-152.	1.4	47
38	Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation. Europace, 2017, 19, 1439-1448.	0.7	47
39	Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. Europace, 2019, 21, 1013-1022.	0.7	47
40	Platelet Isoprostane Overproduction in Diabetic Patients Treated With Aspirin. Diabetes, 2012, 61, 1626-1632.	0.3	46
41	Geriatric Medicine in Italy in the Time of COVID-19. Journal of Nutrition, Health and Aging, 2020, 24, 459-460.	1.5	46
42	Relation of female sex to left atrial diameter and cardiovascular death in atrial fibrillation: The AFFIRM Trial. International Journal of Cardiology, 2016, 207, 258-263.	0.8	43
43	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?. Journal of Arrhythmia, 2018, 34, 99-123.	0.5	41
44	Optimizing Stroke and Bleeding Risk Assessment in Patients with Atrial Fibrillation: A Balance of Evidence, Practicality and Precision. Thrombosis and Haemostasis, 2018, 118, 2014-2017.	1.8	39
45	Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. American Heart Journal, 2016, 181, 83-91.	1.2	38
46	Sex-Specific Cut-Offs for High-Sensitivity Cardiac Troponin: Is Less More?. Cardiovascular Therapeutics, 2019, 2019, 1-12.	1.1	36
47	Nutritional Considerations in Frail Older Patients with COVID-19. Journal of Nutrition, Health and Aging, 2020, 24, 696-698.	1.5	35
48	Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation. Mayo Clinic Proceedings, 2017, 92, 1203-1213.	1.4	34
49	Comparing Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation: A Systematic Review and Meta-Analysis of 81,462 Patients. Journal of Clinical Medicine, 2021, 10, 3979.	1.0	34
50	Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation. Europace, 2018, 20, 243-252.	0.7	33
51	Elderly obese women display the greatest improvement in stair climbing performance after a 3-week body mass reduction program. International Journal of Obesity, 2004, 28, 1097-1104.	1.6	32
52	Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. Europace, 2017, 19, euw150.	0.7	32
53	Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. European Heart Journal, 2021, 42, 3541-3554.	1.0	32
54	Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. EBioMedicine, 2016, 8, 309-316.	2.7	31

#	ARTICLE	IF	CITATIONS
55	Atrial fibrillation prevention: an appraisal of current evidence. <i>Heart</i> , 2018, 104, 882-887.	1.2	31
56	Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2021, 92, 100-106.	1.0	31
57	Relationship between carotid intima-media thickness and non valvular atrial fibrillation type. <i>Atherosclerosis</i> , 2015, 238, 350-355.	0.4	30
58	Ankle-Brachial Index and cardiovascular events in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 856-863.	1.8	30
59	Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry. <i>International Journal of Cardiology</i> , 2018, 271, 68-74.	0.8	30
60	Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2010-2019.	1.1	30
61	Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry. <i>Stroke</i> , 2017, 48, 2198-2205.	1.0	29
62	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. <i>Internal and Emergency Medicine</i> , 2018, 13, 651-660.	1.0	29
63	Systolic Blood Pressure Visit-to-Visit Variability and Major Adverse Outcomes in Atrial Fibrillation. <i>Hypertension</i> , 2017, 70, 949-958.	1.3	28
64	Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. <i>Internal and Emergency Medicine</i> , 2014, 9, 861-870.	1.0	27
65	Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2015, 116, 877-882.	0.7	27
66	Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations. <i>European Journal of Internal Medicine</i> , 2022, 101, 1-7.	1.0	27
67	The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: A systemic review and meta-analysis. <i>International Journal of Cardiology</i> , 2015, 195, 237-242.	0.8	26
68	Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2018, 261, 84-91.	0.8	26
69	Association between clinical risk scores and mortality in atrial fibrillation: Systematic review and network meta-regression of 669,000 patients. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 633-644.	0.8	26
70	Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials). <i>American Journal of Cardiology</i> , 2016, 118, 72-78.	0.7	25
71	Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the REâ€LY trial. <i>Journal of Internal Medicine</i> , 2018, 283, 282-292.	2.7	25
72	The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20 years. <i>Internal and Emergency Medicine</i> , 2020, 15, 1183-1192.	1.0	25

#	ARTICLE	IF	CITATIONS
73	Integrated care and outcomes in patients with atrial fibrillation and comorbidities. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13498.	1.7	25
74	Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 70-84.	1.5	25
75	A Focused Review of Gender Differences in Antithrombotic Therapy. <i>Current Medicinal Chemistry</i> , 2017, 24, 2576-2588.	1.2	25
76	Effect of L-carnitine on oxidative stress and platelet activation after major surgery. <i>Acta Anaesthesiologica Scandinavica</i> , 2011, 55, 1022-1028.	0.7	23
77	Balancing thromboembolic and bleeding risk with non-vitamin K antagonist oral anticoagulants (NOACs): A systematic review and meta-analysis on gender differences. <i>Pharmacological Research</i> , 2017, 117, 274-282.	3.1	23
78	Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 566-572.	0.8	23
79	Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD Bleeding Scores. <i>Journal of the American Heart Association</i> , 2018, 7, e009766.	1.6	23
80	Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. <i>International Journal of Cardiology</i> , 2017, 231, 143-149.	0.8	22
81	Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. <i>Drugs</i> , 2020, 80, 1065-1083.	4.9	22
82	Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. <i>BMC Medicine</i> , 2021, 19, 256.	2.3	22
83	Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study. <i>BMJ Open</i> , 2015, 5, e008026-e008026.	0.8	21
84	Relation of the SAME-TT 2 R 2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials. <i>International Journal of Cardiology</i> , 2016, 216, 168-172.	0.8	21
85	Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials. <i>American Journal of Medicine</i> , 2016, 129, 1110-1116.	0.6	21
86	Inherited and acquired thrombophilia in adults with retinal vascular occlusion: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3249-3266.	1.9	21
87	Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry. <i>American Heart Journal</i> , 2017, 190, 86-93.	1.2	19
88	Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 964-972.	0.8	19
89	Compliance of Atrial Fibrillation Treatment with the Atrial Fibrillation Better Care (ABC) Pathway Improves the Clinical Outcomes in the Middle East Population: A Report from the Gulf Survey of Atrial Fibrillation Events (SAFE) Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 1286.	1.0	19
90	Mobile health technology in atrial fibrillation. <i>Expert Review of Medical Devices</i> , 2022, 19, 327-340.	1.4	19

#	ARTICLE	IF	CITATIONS
91	Ascorbic Acid Infusion Blunts CD40L Upregulation in Patients Undergoing Coronary Stent. <i>Cardiovascular Therapeutics</i> , 2011, 29, 385-394.	1.1	18
92	Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in "real-world" atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. <i>International Journal of Cardiology</i> , 2018, 254, 125-131.	0.8	18
93	Update on extended treatment for venous thromboembolism. <i>Annals of Medicine</i> , 2018, 50, 666-674.	1.5	18
94	Peripheral Arterial Disease in Patients with Atrial Fibrillation: The AFFIRM Study. <i>American Journal of Medicine</i> , 2021, 134, 514-518.	0.6	18
95	VEGF-A gene promoter polymorphisms and microvascular complications in patients with essential hypertension. <i>Clinical Biochemistry</i> , 2010, 43, 1090-1095.	0.8	17
96	Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study. <i>Drugs and Aging</i> , 2018, 35, 365-373.	1.3	17
97	Impact of Sex and Gender on the Efficacy of Antiplatelet Therapy: The Female Perspective. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 109-125.	0.9	16
98	Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older. <i>European Journal of Internal Medicine</i> , 2017, 46, 6-10.	1.0	16
99	Relationship between multimorbidity and outcomes in atrial fibrillation. <i>Experimental Gerontology</i> , 2021, 153, 111482.	1.2	16
100	Role of platelets in NOX2 activation mediated by TNF $\alpha$ in heart failure. <i>Internal and Emergency Medicine</i> , 2014, 9, 179-185.	1.0	15
101	Cerebrovascular disease, associated risk factors and antithrombotic therapy in a population screening cohort: Insights from the Belgian Heart Rhythm Week programme. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 328-334.	0.8	15
102	Appropriateness of prescription of oral anticoagulant therapy in acutely hospitalized older people with atrial fibrillation. Secondary analysis of the SIM $\alpha$ -AF cluster randomized clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2134-2142.	1.1	15
103	Gender-Related Determinants of Adherence to the Mediterranean Diet in Adults with Ischemic Heart Disease. <i>Nutrients</i> , 2020, 12, 759.	1.7	15
104	Clinical Phenotype Classification of Atrial Fibrillation Patients Using Cluster Analysis and Associations with Trial-Adjudicated Outcomes. <i>Biomedicines</i> , 2021, 9, 843.	1.4	15
105	Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, 8, 778-786.	1.8	15
106	Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort. <i>Internal and Emergency Medicine</i> , 2022, 17, 1001-1012.	1.0	15
107	Association Between Peripheral Artery Disease and Incident Risk of Atrial Fibrillation: Strong Evidence Coming From Population-Based Cohort Studies. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	14
108	Sex and Gender Differences in Ischemic Heart Disease: Endocrine Vascular Disease Approach (EVA) Study Design. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 14-25.	1.1	14

#	ARTICLE	IF	CITATIONS
109	Incidence and Predictors of Infections and All-Cause Death in Patients with Cardiac Implantable Electronic Devices: The Italian Nationwide RI-AIAC Registry. <i>Journal of Personalized Medicine</i> , 2022, 12, 91.	1.1	14
110	Usefulness of Red Cells Distribution Width to Predict Worse Outcomes in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 124, 1561-1567.	0.7	13
111	Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: A systematic review and meta-regression. <i>European Journal of Internal Medicine</i> , 2022, 103, 84-94.	1.0	13
112	Growth hormone responses to repeated bouts of aerobic exercise with different recovery intervals in cyclists. <i>Journal of Endocrinological Investigation</i> , 2005, 28, RC11-RC14.	1.8	12
113	Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2013, 168, 3241-3247.	0.8	12
114	Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018, 122, 785-792.	0.7	12
115	Screening for atrial fibrillation: Need for an integrated, structured approach. <i>European Journal of Internal Medicine</i> , 2019, 67, 33-35.	1.0	12
116	Sex-related differences in prevalence, treatment and outcomes in patients with atrial fibrillation. <i>Internal and Emergency Medicine</i> , 2020, 15, 231-240.	1.0	12
117	Describing the relationship between atrial fibrillation and frailty: Clinical implications and open research questions. <i>Experimental Gerontology</i> , 2021, 152, 111455.	1.2	12
118	Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry. <i>Europace</i> , 2022, 24, 721-728.	0.7	12
119	A multinational European network to implement integrated care in elderly multimorbid atrial fibrillation patients: the AFFIRMO Consortium. <i>European Heart Journal</i> , 2022, 43, 2916-2918.	1.0	12
120	The combined effect of adiposity, fat distribution and age on cardiovascular risk factors and motor disability in a cohort of obese women (aged 18-83). <i>Journal of Endocrinological Investigation</i> , 2006, 29, 905-912.	1.8	11
121	Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , 2014, 46, 632-638.	0.4	11
122	Obesity Paradox in Atrial Fibrillation: Implications for Outcomes and Relationship with Oral Anticoagulant Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 125-137.	1.0	11
123	The Compelling Issue of Nonvitamin K Antagonist Oral Anticoagulant Adherence in Atrial Fibrillation Patients: A Systematic Need for New Strategies. <i>Thrombosis and Haemostasis</i> , 2020, 120, 369-371.	1.8	11
124	Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials. <i>International Journal of Cardiology</i> , 2018, 252, 96-100.	0.8	10
125	Clinical features and management of venous thromboembolism in patients with Behçet's syndrome: a single-center case-control study. <i>Internal and Emergency Medicine</i> , 2020, 15, 635-644.	1.0	10
126	COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemia. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1576-1578.	2.8	10



#	ARTICLE	IF	CITATIONS
127	Compliance of atrial fibrillation treatment with the ABC pathway in patients with concomitant diabetes mellitus in the Middle East based on the Gulf SAFE registry. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13385.	1.7	10
128	Prevalence of New-Onset Atrial Fibrillation and Associated Outcomes in Patients with Sepsis: A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 547.	1.1	10
129	Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase. <i>International Journal of Cardiology</i> , 2017, 248, 166-172.	0.8	9
130	Screening for Atrial Fibrillation in Relation to Stroke and Mortality Risk. <i>Thrombosis and Haemostasis</i> , 2022, 122, 171-175.	1.8	9
131	Risk prediction of clinical adverse outcomes with machine learning in a cohort of critically ill patients with atrial fibrillation. <i>Scientific Reports</i> , 2021, 11, 18925.	1.6	9
132	Asymptomatic peripheral artery disease and antiplatelet management. <i>Vasa - European Journal of Vascular Medicine</i> , 2014, 43, 309-325.	0.6	8
133	Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards. <i>European Journal of Internal Medicine</i> , 2018, 52, e12-e14.	1.0	8
134	Simulation-Based Education for Physicians to Increase Oral Anticoagulants in Hospitalized Elderly Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2019, 132, e634-e647.	0.6	8
135	Impact of atrial fibrillation in critically ill patients admitted to a stepdown unit. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13317.	1.7	8
136	Lack of energy is associated with malnutrition in nursing home residents: Results from the <sc>INCUR</sc> study. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 3242-3248.	1.3	8
137	Old And New Oral Anticoagulants In Management Of Atrial Fibrillation: A Double-Edged Sword For Women. <i>Current Vascular Pharmacology</i> , 2015, 13, 738-748.	0.8	8
138	CHA2DS2-VASc score stratifies mortality risk in heart failure patients aged 75 years and older with and without atrial fibrillation. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 1707-1720.	1.4	8
139	Use and Prescription of Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Multidisciplinary Consensus Document. <i>Journal of Personalized Medicine</i> , 2022, 12, 469.	1.1	8
140	Antidotes to non-vitamin K oral anticoagulants: necessary or not?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1573-1576.	0.9	7
141	Atrial Fibrillation and Stroke. <i>Cardiology Clinics</i> , 2016, 34, 317-328.	0.9	7
142	Relationship Between Use of Videogames and Sexual Health in Adult Males. <i>Journal of Sexual Medicine</i> , 2017, 14, 898-903.	0.3	7
143	Testosterone-to-estradiol ratio and platelet thromboxane release in ischemic heart disease: the EVA project. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1367-1377.	1.8	7
144	The Sex-Specific Detrimental Effect of Diabetes and Gender-Related Factors on Pre-admission Medication Adherence Among Patients Hospitalized for Ischemic Heart Disease: Insights From EVA Study. <i>Frontiers in Endocrinology</i> , 2019, 10, 107.	1.5	6

#	ARTICLE	IF	CITATIONS
145	Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f84-f92.	1.4	6
146	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13773.	1.7	6
147	Bleeding related to non-vitamin K antagonist oral anticoagulants in emergency department: A real-world snapshot from Southern Italy. On behalf of MIRC-NOAC study group. <i>European Journal of Internal Medicine</i> , 2018, 48, e21-e24.	1.0	5
148	Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1483-1488.	0.9	5
149	Explanatory power of gender relations in cardiovascular outcomes: the missing piece of the puzzle. <i>Heart</i> , 2018, 104, 1900-1901.	1.2	5
150	Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 1313-1317.e9.	1.2	5
151	Tailored oral anticoagulant prescription in patients with atrial fibrillation: Use and misuse of clinical risk prediction scores. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 726-728.	0.8	5
152	Towards an integrated approach to violence against women: persistence, specificity and complexity. <i>International Review of Sociology</i> , 2020, 30, 249-278.	0.7	5
153	Predictors of drug prescription in nursing home residents: results from the INCUR study. <i>Internal and Emergency Medicine</i> , 2022, 17, 165-171.	1.0	5
154	Kidney Function According to Different Equations in Patients Admitted to a Cardiology Unit and Impact on Outcome. <i>Journal of Clinical Medicine</i> , 2022, 11, 891.	1.0	5
155	Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. <i>European Journal of Internal Medicine</i> , 2022, 99, 45-56.	1.0	5
156	Edoxaban in venous thromboembolism and stroke prevention: an appraisal. <i>Vascular Health and Risk Management</i> , 2016, 12, 45.	1.0	4
157	Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>Clinical Research in Cardiology</i> , 2017, 106, 420-427.	1.5	4
158	Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1107-1114.	1.8	4
159	Driving restriction in patients with cardiac implantable electronic devices: an overview of worldwide regulations. <i>Expert Review of Medical Devices</i> , 2020, 17, 297-308.	1.4	4
160	Atrial high rate episodes as a marker of atrial cardiomyopathy: In the quest of the Holy Grail. Author's reply. <i>European Journal of Internal Medicine</i> , 2022, 98, 115-116.	1.0	4
161	Epidemiology of cerebral microbleeds and risk of adverse outcomes in atrial fibrillation: a systematic review and meta-analysis. <i>Europace</i> , 2022, 24, 1395-1403.	0.7	4
162	Renal Function, Cardiovascular Diseases, Appropriateness of Drug Prescription and Outcomes in Hospitalized Older Patients. <i>Drugs and Aging</i> , 2021, 38, 1097-1105.	1.3	4

#	ARTICLE	IF	CITATIONS
163	Reply. Journal of the American College of Cardiology, 2017, 69, 1212.	1.2	3
164	Autonomic dysfunction and cardiovascular risk in patients with atherosclerotic renal artery stenosis: A pilot study. European Journal of Internal Medicine, 2018, 52, e19-e21.	1.0	3
165	Biomarkers in Heart Failure and Associated Diseases. Disease Markers, 2019, 2019, 1-2.	0.6	3
166	Cardiomyopathy associated with long-term right ventricular pacing: an intriguing clinical issue. European Journal of Heart Failure, 2019, 21, 652-654.	2.9	3
167	Pain Management in Nursing Home Residents: Results from the Incur Study. Journal of Nutrition, Health and Aging, 2020, 24, 1019-1022.	1.5	3
168	Impact of rate control in hospitalized patients with atrial fibrillation and sepsis. European Journal of Internal Medicine, 2021, 89, 126-128.	1.0	3
169	Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10%220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry. European Journal of Preventive Cardiology, 0, . . .	0.8	3
170	Atrial fibrillation is not associated with increased risk of venous thromboembolism: Results from ARAPACIS study. Thrombosis and Haemostasis, 2015, 114, 655-655.	1.8	2
171	Outcome of octogenarians with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. Clinical Cardiology, 2017, 40, 1264-1270.	0.7	2
172	Impact of revascularization procedures on Doppler parameters in patients with atherosclerotic renal artery stenosis. European Journal of Internal Medicine, 2018, 51, e28-e29.	1.0	2
173	Use of NOACs in the Peri-Operative Management of Patients with Atrial Fibrillation: To Stop, Bridge or Continue?. Thrombosis and Haemostasis, 2018, 118, 1123-1126.	1.8	2
174	Pain Management in Nursing Home Residents: Results from the Incur Study. Journal of Nutrition, Health and Aging, 2020, 24, 1019-1022.	1.5	2
175	A comprehensive appraisal of dabigatran etexilate clinical evidence and applications: a 10-year-long story. Future Cardiology, 2021, 17, 215-226.	0.5	2
176	Management of Ventricular Heart Rate in Atrial Fibrillation Patients With Sepsis. Chest, 2021, 159, 1315-1316.	0.4	2
177	Effectiveness and safety of high and low dose NOACs in patients with atrial fibrillation. European Journal of Internal Medicine, 2021, 88, 118-122.	1.0	2
178	Screening for Atrial Fibrillation in Relation to Stroke and Mortality Risk. Thrombosis and Haemostasis, 2021, , .	1.8	2
179	Reply. Journal of the American College of Cardiology, 2014, 63, 1457-1458.	1.2	1
180	Non-steroidal anti-inflammatory drugs and incident atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 115-116.	1.4	1

#	ARTICLE	IF	CITATIONS
181	Geographical differences in thromboembolic and bleeding risks in patients with non-valvular atrial fibrillation: An ancillary analysis from the SPORTIF trials. <i>International Journal of Cardiology</i> , 2017, 236, 244-248.	0.8	1
182	Heart rate variability in nephrotic syndrome: Role of sympathetic and parasympathetic system. <i>European Journal of Internal Medicine</i> , 2018, 54, e21-e22.	1.0	1
183	Risk stratification in hospitalized heart failure patients: do the RIGHT thing!. <i>Internal and Emergency Medicine</i> , 2019, 14, 1021-1023.	1.0	1
184	Diuretic resistance in decompensated chronic heart failure: trying to get out of the "œloop". <i>Internal and Emergency Medicine</i> , 2019, 14, 497-498.	1.0	1
185	Management of peripheral arterial disease in the modern era: an internist "œCup of Tea". <i>Internal and Emergency Medicine</i> , 2020, 15, 195-197.	1.0	1
186	598 IN VITRO EFFECT OF n-6/n-3 POLYUNSATURATED FATTY ACIDS ON PLATELET NOX2-MEDIATED OXIDATIVE STRESS IN LIVER CIRRHOSIS. <i>Journal of Hepatology</i> , 2013, 58, S244-S245.	1.8	0
187	LexMeter: Validation of an Automated System for the Assessment of Lexical Competence of Medical Students as a Prerequisite for the Development of an Adaptive e-learning System. <i>Frontiers in ICT</i> , 2015, 2, .	3.6	0
188	GW26-e2301 The CHADS 2 and CHA 2 DS 2 -VASc scores for predicting ischemic stroke amongst Asian patients with atrial fibrillation: A systemic review and meta-analysis. <i>Journal of the American College of Cardiology</i> , 2015, 66, C271.	1.2	0
189	Moving Beyond Traditional Cardiovascular Risk Factors Toward Gendered Horizon. <i>Journal of Women's Health</i> , 2017, 26, 600-601.	1.5	0
190	5769 Changes in thromboembolic risk profile and antithrombotic therapy use over a decade: a comparison of Euro Heart Survey on AF and EURObservational research programme AF pilot registry. <i>European Heart Journal</i> , 2017, 38, .	1.0	0
191	P4012 Antiplatelet therapy and adverse outcomes in high cardiovascular risk elderly patients: a sex and gender focused analysis from REPOSI study. <i>European Heart Journal</i> , 2017, 38, .	1.0	0
192	The dangerous combination of atrial fibrillation and hypertension: An urgent need to handle complexity. <i>International Journal of Cardiology</i> , 2018, 254, 167-169.	0.8	0
193	4366 Estimated effectiveness and safety of non-vitamin K antagonist oral anticoagulants compared to optimally anticoagulated real-world atrial fibrillation patients taking acenocoumarol. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
194	Evolving concepts in atrial fibrillation epidemiology: Advancing knowledge about cardiovascular health in sub-Saharan Africa. <i>International Journal of Cardiology</i> , 2018, 271, 115-116.	0.8	0
195	Managing thromboembolic risk in patients with subclinical atrial fibrillation: A new challenge for the clinical cardiologist. <i>International Journal of Cardiology</i> , 2019, 296, 89-90.	0.8	0
196	Impact of hospitalization in patients with atrial fibrillation: Implications for health-care providers and clinical management. <i>International Journal of Cardiology</i> , 2019, 276, 287-288.	0.8	0
197	Antithrombotic treatment strategies after PCI. <i>Lancet, The</i> , 2020, 395, 866.	6.3	0
198	Impact of malignancy on outcomes in European patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in Atrial Fibrillation General Long-Term Registry. <i>European Heart Journal</i> , 2021, 42, .	1.0	0

#	ARTICLE	IF	CITATIONS
199	Growth hormone responses to repeated bouts of aerobic exercise with different recovery intervals. <i>Journal of Applied Physiology</i> , 2006, 100, 1093-1094.	1.2	0
200	Prognostic impact of renal function trajectories and temporal variability amongst anticoagulated atrial fibrillation patients: a subgroup analysis of the SPORTIF III and V trials. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
201	Abstract 15492: The Prognostic Role of Education Attainment Level in Individuals With Ischemic Heart Disease: Analysis From the Endocrine Vascular Approach Study. <i>Circulation</i> , 2020, 142, .	1.6	0
202	Impact of old and very old age on outcomes in patients with acute ischemic stroke undergoing endovascular therapy. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
203	Anticoagulation for Thromboprophylaxis in Patients with Intracerebral Hemorrhage: Less Room for Scepticism. <i>Thrombosis and Haemostasis</i> , 2022, 0, .	1.8	0
204	The case of diabetes mellitus and atrial fibrillation: Underlining the importance of non-cardiovascular comorbidities. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	0